trial for Debbie Summergold2

[Summergold2]

for got to post the number of the trialDS6000-A-U101 clinical trial, NCT 04707248.

[RomanZ]

Hi Debbie,

This is an antibody drug conjugate called Raludotatug Deruxtecan (R-DXd), which specifically targets CDH6 cells which are over expressed in ovarian cancer. They just reported on the phase 1 trial, which included heavily pre-treated and platinum resistant women with ovarian cancer. The results are very encouraging. The response rate was 46% and there was one complete response and 22 partial responses (partial response usually means reduction in tumour size). The median duration of response was 11.2 months. These are very encouraging efficacy results, especially because phase 1 trails primarily test for tolerability.

I hope your team can help you get into the trial. This is a very new drug and the world of cancer treatment is progressing very quickly.